
Releases
Menarini Reports Positive Phase 3 SENTRY Trial Data for Myelofibrosis
The combination of selinexor and ruxolitinib has met a primary endpoint in the Phase 3 SENTRY trial, demonstrating a statistically significant reduction in spleen volume for patients with frontline myelofibrosis. Presented at the EHA 2026 Congress, the results highlight a potential shift in treatment efficacy for this rare blood cancer.




















